Striking the delicate balance of externalizing biopharma R&D to maximize innovation: Strategies to buy vs. build

[Available On-Demand] ・ Click video to start playback;Join chat Q&A below video
Search General Info
Six of the top ten biggest selling biopharmaceuticals were acquired or in-licensed. In parallel, the R&D spend of the industry has remained at 16.8% (5.6-24.3%) of revenue over a long period of time. In parallel, evidence shows that more product candidates are entering Phase 1-2 stage of testing in the last decade than before. However, they are not necessarily resulting into de-risked, late-stage biopharma pipelines.
Another wave of loss of exclusivity estimated approximately $160B is quickly approaching creating the need to innovate fast. Given these dynamics, the sense of urgency to replenish the in-market assets could not be more acute. Thankfully, the high-risk high-reward nature of the industry has been benefiting from a healthy cash-flow which built a collective firepower estimated at $1.2T which can be deployed to acquisitions. To respond to the shortfall in the R&D productivity and fuel top-line growth, the Biopharma industry has to strike the delicate balance of buy vs. build.
Moderator
photo
Partner
EY
Speakers
photo
Global Head of Business Development & Licensing, Executive Committee Member
Bayer Pharmaceuticals
photo
Founder and Senior Advisor
Aisling Capital
photo
Professor of Economics
SRH University Heidelberg
photo
Partner
EY
photo
Vice President of Worldwide Business Development
Pfizer Inc.